Skip to main content
An official website of the United States government

Supportive Care and Symptom Management

The Supportive Care and Symptom Management program supports studies on the prevention or treatment of acute and chronic symptoms and morbidities related to cancer and its treatment. This includes the impact on the quality of life of patients and their informal caregivers. The program also supports studies of patients and their caregivers at the end of life.

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Supportive Care and Symptom Management

The program supports research in three areas: prevention or treatment of acute or chronic symptoms and morbidities related to cancer, its treatment and caregiving (symptom management research); effects on quality of life from cancer, its treatment and caregiving (quality of life research); and end-of-life psychosocial issues, caregiving and treatment strategies (end-of-life research).

Through the NCI Community Oncology Research Program (NCORP), clinical trials are underway to evaluate therapies to prevent or ameliorate a broad range of symptoms and/or toxicities associated with cancer its treatment and caregiving. Other studies funded separately are investigating a range of treatment effects on health-related quality of life and a variety of influences on the end-of-life cancer experience. 

Topic Areas include: Anorexia, Cachexia, Cardiotoxicity, Caregiver Issues, Cognitive Dysfunction, Distress/Anxiety/Depression, End of Life, Fatigue, Geriatrics, Hot Flashes, Lymphedema, Medication Adherence, Mucositis, Multiple Symptoms, Musculoskeletal Symptoms, Nausea, Neuropathy, Nutrition, Oral Complications, Other Supportive Care Issues, Pain, Palliative Care, Pediatrics/Adolescents/Young Adult, Physical Functioning, Quality of Life, Skin Toxicities, Sleep Disorders, and Urinary Complications.

Selected Topics

Funding Opportunities

No matching Funding Opportunities were found.

View All Funding Opportunities

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Garcia, Jose M.

Seattle Inst For Biomedical/Clinical Res
United States

SArcopenia in Men with Prostate Cancer undergoing ADT (SAP-ADT) 5R01CA279220-02 Marjorie Perloff, M.D.
Garcia, Jose M.

Seattle Inst For Biomedical/Clinical Res
United States

SArcopenia in Men with Prostate Cancer undergoing ADT (SAP-ADT) 5R01CA279220-02 Marjorie Perloff, M.D.
Geisler, Stefanie

Washington University
United States

Developing mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy 5R37CA267905-04 Asad Umar, D.V.M., Ph.D.
Geisler, Stefanie

Washington University
United States

Developing mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy 5R37CA267905-04 Asad Umar, D.V.M., Ph.D.
Germain, Doris A

Icahn School Of Medicine At Mount Sinai
United States

Investigating the efficacy of g-Tocotrienol for the prevention of post-partum breast cancer 1R01CA301372-01 Anda Vlad, M.D., Ph.D.
Germain, Doris A

Icahn School Of Medicine At Mount Sinai
United States

Exploring ovarian-derived hormone STC1 as the mediator of the protective effect of breast feeding against breast cancer. 5R21CA270702-02 Marjorie Perloff, M.D.
Ghamande, Sharad A.

Augusta University
United States

Georgia CaRes 3UG1CA189851-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Ghamande, Sharad A.

Augusta University
United States

Georgia CaRes 3UG1CA189851-11S1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Ghobrial, Irene M.

Dana-Farber Cancer Inst
United States

Myeloma multidimensional precancer atlas 4U01CA294507-02 Nicholas Hodges, Ph.D.
Ghobrial, Irene M.

Dana-Farber Cancer Inst
United States

Molecular prediction of myeloma in African Americans 5U01CA271492-04 Claire Zhu, Ph.D.
Ghosh, Jayashri

Temple Univ Of The Commonwealth
United States

Development of blood-based methylation biomarkers for CRC risk prediction 5R01CA281948-03 Matthew Young, Ph.D.
Giles, Erin

University Of Michigan At Ann Arbor
United States

Obesity, body fat distribution, and breast cancer risk: is visceral fat the culprit after menopause? 5R01CA269726-02 Marjorie Perloff, M.D.
Gill, Brian John Andrew

Columbia University Health Sciences
United States

The Impact of Local and Reversible Change to GABAergic Inhibitory Signaling on Tumor-Induced Cortical Dysfunction in Glioma 1R01NS140658-01A1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Gill, Brian John Andrew

Columbia University Health Sciences
United States

The Impact of Local and Reversible Change to GABAergic Inhibitory Signaling on Tumor-Induced Cortical Dysfunction in Glioma 1R01NS140658-01A1 Brandy Heckman-Stoddard, Ph.D., M.P.H.
Godwin, Andrew K.

University Of Kansas Medical Center
United States

Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem 5R01CA260132-05 Matthew Young, Ph.D.

Clinical Trials

Status

No matching Clinical Trials were found.

View All Clinical Trials